MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR

摘要: Background: Methylation of the O 6 -methylguanine-DNA methyltransferase (MGMT) gene promoter is a favorable prognostic factor in glioblastoma patients. However, reported methylation frequencies vary significantly partly due to lack consensus choice analytical method. Method: We examined 35 low- and 99 high-grade gliomas using quantitative specific PCR (qMSP) pyrosequencing. Gene expression level MGMT was analyzed by RT-PCR. Results: When qMSP, 26% low-grade 37% were found be methylated, whereas 97% 55% methylated The average lower group patients with independent method used for detection. Primary (as evaluated both detection methods) had approximately 5 months longer median survival compared an unmethylated (log-rank test; pyrosequencing P = .02, qMSP .06). One third samples conflicting results when comparing data from overall analysis shows that these have intermediate prognosis between groups concordant two methods. Conclusion: In our opinion, gives sufficient information merit its inclusion standard management gliomas, this study came across as better